Pituitary adenomas – practical approach to the diagnosis and the changes in the 2017 WHO classification

Česká verzia

Authors: Boris Rychlý ¹; Magdaléna Puchertová ²; Marián Švajdler ^3,4; Josef Zámečník ⁵
Authors place of work: Alpha medical, s. r. o., Bratislava, Slovenská republika ¹; Ústav patologickej anatómie, Slovenská zdravotnícka univerzita, Bratislava, Slovenská republika ²; Šiklův ústav patologie, Univerzita Karlova v Praze, Lékařská fakulta v Plzni a Fakultní nemocnice Plzeň, Česká republika ³; Bioptická laboratoř, s. r. o., Plzeň, Česká republika 5 Ústav patologie a molekulární medicíny 2. LF UK a FN v Motole, Praha, Česká republika ⁴
Published in the journal: Čes.-slov. Patol., 55, 2019, No. 3, p. 137-144
Category: Přehledový článek

Summary

The histopathological diagnosis of sellar tumors is a difficult area of the diagnostic surgical pathology. The most common sellar tumor is a pituitary adenoma. The histomorphology of pituitary adenomas is very heterogeneous, and in the sellar area, we can encounter practically any other tumor known from human pathology, either primary or secondary. Exact histopathological classification requires many immunohistochemical antibodies: pituitary hormones, pituitary transcription factors, and several other antibodies. At present, electron microscopy is no longer necessary for the routine diagnosis of the pituitary gland adenomas. The important aspect of the precise classification is to screen pituitary adenomas for aggressive histological types. The latest edition of the WHO classification of tumours of endocrine organs, published in 2017, involves several changes in the chapter of pituitary adenomas, including the abolition of the concept of atypical adenoma. In the short review, we discuss the practical approach to the diagnosis and the changes in the latest WHO classification of pituitary adenomas from 2017.

Keywords:

Pituitary adenoma – histopathology – WHO classification 2017

Zdroje

Mete O, Cintosun A, Pressman I, Asa SL. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol 2018; 31(6): 900-909.
Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004; 101(3): 613–619.
Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs (4th ed). Geneva: WHO Press; 2017: 11-63.
Thompson LD, Seethala RR, Müller S. Ectopic sphenoid sinus pituitary adenoma (ESSPA) with normal anterior pituitary gland: a clinicopathologic and immunophenotypic study of 32 cases with a comprehensive review of the english literature. Head Neck Pathol 2012; 6(1): 75-100.
Hyrcza MD, Ezzat S, Mete O, Asa SL. Pituitary adenomas presenting as sinonasal or nasopharyngeal masses: a case series illustrating potential diagnostic pitfalls. Am J Surg Pathol 2017; 41(4): 525–534.
Asa SL, Ezzat S. Aggressive pituitary tumors or localized pituitary carcinomas: defining pituitary tumors. Expert Rev Endocrinol Metab 2016; 11(2): 149-162.
Asa SL, Casar-Borota O, Chanson P, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 2017; 24(4): 6-8.
Jarzembowski J, Lloyd R, McKeever P. Type IV collagen immunostaining is a simple, reliable diagnostic tool for distinguishing between adenomatous and normal pituitary glands. Arch Pathol Lab Med 2007; 131(6): 931-935.
Lacruz CR, Saenz de Santamaria J, Bardales RH. Central Nervous System Intraoperative Cytopathology (2nd edn). Cham: Springer; 2018: 373-379.
Afroz N, Khan N, Hassan J, Huda MF. Role of imprint cytology in the intraoperative diagnosis of pituitary adenomas. Diagn Cytopathol 2011; 39(2): 138-140.
Asa SL. Tumors of the Pituitary Gland (4th ed). Washington: AFIP; 2011: 249-255.
Nishioka H, Inoshita N, Mete O, et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 2015; 26(4): 349–355.
McDonald WC, Banerji N, McDonald KN, Ho B, Macias V, Kajdacsy-Balla A. Steroidogenic factor 1, Pit-1, and adrenocorticotropic hormone: a rational starting place for the immunohistochemical characterization of pituitary adenoma. Arch Pathol Lab Med 2017; 141(1): 104-112.
Sjöstedt E, Bollerslev J, Mulder J, Lindskog C, Pontén F, Casar-Borota O. A specific antibody to detect transcription factor T-Pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours. Acta Neuropathol 2017; 134(4): 675-677.
Asa SL, Bamberger AM, Cao B, Wong M, Parker KL, Ezzat S. The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab 1996; 81(6): 2165–2170.
Sbiera S, Schmull S, Assie G, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab 2010; 95(10): 161-171.
Sangoi AR, McKenney JK, Brooks JD, Higgins JP. Evaluation of SF-1 expression in testicular germ cell tumors: a tissue microarray study of 127 cases. Appl Immunohistochem Mol Morphol 2013; 21(4) :318-321.
Delellis RA, Lloyd RV, Heitz PU. Pathology and genetics of tumours of endocrine organs (3rd edn). Lyon: IARC Press; 2004: 9-48.
Larkin S, Reddy R, Karavitaki N, Cudlip W, Wass J, Ansorge O. Granulationpattern, but not GSP or GHR mutation, is associated with clinical characteristicsin somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol 2013; 168(4): 491–499.
Obari A, Sano T, Ohyama K, et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol. 2008; 19(2): 82-91.
Sano T, Rong QZ, Kagawa N, Yamada S. Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas. Front Horm Res 2004; 32: 127–132.
Mete O, Asa SL. Clinicopathological correlations in pituitary adenomas. Brain Pathol 2012; 22(4): 443-453.
Liu Y, Yao Y, Xing B, et al. Prolactinomas in children under 14. Clinical presentation and long-term follow-up. Childs Nerv Syst 2015; 31(6): 909-916.
Mete O, Asa SL. Therapeutic implications of accurate classification of pituitary adenomas. Semin Diagn Pathol 2013; 30(3): 158-164.
Horvath E, Kovacs K, Singer W, et al. Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer 1981; 47(4): 761-771.
Wang EL, Qian ZR, Yamada S, et al. Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas. Endocr Pathol 2009; 20(4): 209-220.
Buliman A, Tataranu LG, Paun DL, Mirica A, Dumitrache C. Cushing‘s disease: a multidisciplinary overview of the clinical features, diagnosis, and treatment. J Med Life 2016; 9(1): 12-18.
George DH, Scheithauer BW, Kovacs K, et al. Crooke‘s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 2003; 27(10): 1330-1336.
Cooper O. Silent Corticotroph Adenomas. Pituitary 2015; 18(2): 225–231.
Tutal E, Yılmazer D, Demirci T, et al. A rare case of ectopic ACTH syndrome originating from malignant renal paraganglioma. Arch Endocrinol Metab 2017; 61(3): 291-295.
Byun J, Kim SH, Jeong HS, et al. ACTH-producing neuroendocrine tumor of the pancreas: a case report and literature review. Ann Hepatobiliary Pancreat Surg 2017; 21(1): 61–65.
Neumann PE, Horoupian DS, Goldman JE, Hess MA. Cytoplasmic filaments of Crooke‘s hyaline change belong to the cytokeratin class. An immunocytochemical and ultrastructural study. Am J Pathol 1984; 116(2): 214–222.
Crooke A. Change in the basophil cells of the pituitary gland common to conditions which exhibit the syndrome attributed to basophil adenoma. J Pathol Bacteriol 1935; 41(2): 339–349.
Ho DM, Hsu CY, Ting LT, Chiang H. The clinicopathological characteristics of gonadotroph cell adenoma: a study of 118 cases. Hum Pathol. 1997; 28(8): 905-911.
Kovacs K, Horvath E, Ryan N, Ezrin C. Null cell adenoma of the human pituitary. Virchows Arch A Pathol Anat Histol. 1980; 387(2): 165–174.
Asa SL, Mete O. Immunohistochemical biomarkers in pituitary pathology. Endocr Pathol 2018; 29(2): 130-136.
Casar-Borota O, Botling J, Granberg D, et al. Serotonin, ATRX, and DAXX expression in pituitary adenomas: markers in the differential diagnosis of neuroendocrine tumors of the sellar region. Am J Surg Pathol 2017; 41(9): 1238-1246.
Miettinen M, McCue PA, Sarlomo-Rikala M. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial andnonepithelial tumors. Am J Surg Pathol 2014; 38(1): 13–22.
Osinga TE, Korpershoek E, de Krijger RR, et al. Catecholamine-synthesizing enzymes are expressed in parasympathetic head and neck paraganglioma tissue.Neuroendocrinology 2015; 101(4): 289–295.
Toledo RA, Burnichon N, Cascon A, et al. Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nat Rev Endocrinol 2017; 13(4): 233-247.
Gill AJ, Toon CW, Clarkson A, et al. Succinate dehydrogenase deficiency is rare in pituitary adenomas. Am J Surg Pathol 2014;38(4):560–566.
Scheithauer BW, Horvath E, Kovacs K, Laws ER Jr, Randall RV, Ryan N. Plurihormonal pituitary adenomas. Semin Diagn Pathol 1986; 3(1): 69-82.
Ogando-Rivas E, Alalade AF, Boatey J, Schwartz TH. Double pituitary adenomas are most commonly associated with GH- and ACTH-secreting tumors: systematic review of the literature. Pituitary 2017; 20(6): 702-708.
Amar AP, Hinton DR, Krieger MD, Weiss MH. Invasive pituitary adenomas: significance of proliferation parameters. Pituitary 1999; 2(2): 117-122.
Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996; 38(1): 99-106.
Heaney AP. Pituitary Carcinoma: Difficult Diagnosis and Treatment. J Clin Endocrinol Metab 2011; 96(12): 3649–3660.
Scheithauer BW, Kovacs KT, Laws ER, Jr, Randall RV. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 1986; 65(6): 733-744.
Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005; 90(5): 3089-3099.
Bush ZM, Longtime JA, Cunningham T, et al. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 2010; 95(11): 280-290.
Hirohata T, Asano K, Ogawa Y, et al. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by Japan Society for hypothalamic and pituitary Tumors. J Clin Endocrinol Metab 2013; 98(3): 1130-1136.
Scheithauer BW, Kovacs K, Horvath E, et al. Pituitary blastoma. Acta Neuropathol 2008; 116(6): 657-666.
Scheithauer BW, Horvath E, Abel TW, et al. Pituitary blastoma: a unique embryonaltumor. Pituitary 2012; 15(3): 365-373.
Sahakitrungruang T, Srichomthong C, Pornkunwilai S, et al. Germline and somatic DICER1 mutations in a pituitary blastoma causing infantile-onset Cushing’s disease. J Clin Endocrinol Metab 2014; 99(8): 1487-1492.